$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

$csbr Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000162828017009317 Filed on September 14, 2017

Income Statement

Concept	2017 Q3	2016 Q3
Revenue	$5.033M	$3.670M
YoY Change	37.14%	30.05%
Cost Of Revenue	$2.642M	$2.520M
YoY Change	4.84%	11.01%
Gross Profit	$2.391M	$1.150M
YoY Change	107.91%	109.09%
Gross Profit Margin	47.51%	31.34%
Selling, General & Admin	$1.892M	$2.459M
YoY Change	-23.06%	4.82%
% of Gross Profit	79.13%	213.83%
Research & Development	$1.118M	$1.211M
YoY Change	-7.68%	10.09%
% of Gross Profit	46.76%	105.3%
Depreciation & Amortization	$36.00K	$39.00K
YoY Change	-7.69%	5.41%
% of Gross Profit	1.51%	3.39%
Operating Expenses	$5.652M	$6.193M
YoY Change	-8.74%	8.29%
Operating Profit	-$619.0K	-$2.523M
YoY Change	-75.47%	-12.91%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$51.00K	-$9.000K
YoY Change	466.67%	-10.0%
Pretax Income	-$670.0K	-$2.532M
YoY Change	-73.54%	-12.9%
Income Tax	$4.000K	$14.00K
% Of Pretax Income
Net Earnings	-$674.0K	-$2.546M
YoY Change	-73.53%	-12.6%
Net Earnings / Revenue	-13.39%	-69.37%
Basic Earnings Per Share	-$0.06
Diluted Earnings Per Share	-$0.06	-$259.1K
COMMON SHARES
Basic Shares Outstanding	10.98M shares	9.835M shares
Diluted Shares Outstanding	10.98M shares

Balance Sheet

Concept	2017 Q3	2016 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$430.0K	$4.460M
YoY Change	-90.36%	-34.02%
Cash & Equivalents	$400.0K	$4.463M
Short-Term Investments
Other Short-Term Assets	$360.0K	$350.0K
YoY Change	2.86%	-5.41%
Inventory
Prepaid Expenses
Receivables	$2.667M	$1.628M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$3.457M	$6.440M
YoY Change	-46.32%	-24.94%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.084M	$590.0K
YoY Change	253.22%	31.11%
Goodwill	$669.0K	$669.0K
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$107.0K	$150.0K
YoY Change	-28.67%	0.0%
Total Long-Term Assets	$3.010M	$1.409M
YoY Change	113.63%	10.94%
TOTAL ASSETS
Total Short-Term Assets	$3.457M	$6.440M
Total Long-Term Assets	$3.010M	$1.409M
Total Assets	$6.467M	$7.849M
YoY Change	-17.61%	-20.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.732M	$1.509M
YoY Change	14.78%	4.79%
Accrued Expenses	$551.0K	$220.0K
YoY Change	150.45%	-47.62%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$30.00K
YoY Change
Total Short-Term Liabilities	$6.020M	$4.426M
YoY Change	36.01%	17.71%
LONG-TERM LIABILITIES
Long-Term Debt	$30.00K	$0.00
YoY Change
Other Long-Term Liabilities	$157.0K	$247.0K
YoY Change	-36.44%	30.0%
Total Long-Term Liabilities	$157.0K	$247.0K
YoY Change	-36.44%	30.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.020M	$4.426M
Total Long-Term Liabilities	$157.0K	$247.0K
Total Liabilities	$6.177M	$4.673M
YoY Change	32.18%	18.3%
SHAREHOLDERS EQUITY
Retained Earnings	-$70.02M	-$65.01M
YoY Change	7.71%
Common Stock	$71.57M	$69.44M
YoY Change	3.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.252M	$1.252M
YoY Change	0.0%
Treasury Stock Shares	269.7K shares	269.7K shares
Shareholders Equity	$290.0K	$3.176M
YoY Change
Total Liabilities & Shareholders Equity	$6.467M	$7.849M
YoY Change	-17.61%	-20.31%

Cashflow Statement

Concept	2017 Q3	2016 Q3
OPERATING ACTIVITIES
Net Income	-$674.0K	-$2.546M
YoY Change	-73.53%	-12.6%
Depreciation, Depletion And Amortization	$36.00K	$39.00K
YoY Change	-7.69%	5.41%
Cash From Operating Activities	-$1.948M	-$2.439M
YoY Change	-20.13%	-4.09%
INVESTING ACTIVITIES
Capital Expenditures	$910.0K	$17.00K
YoY Change	5252.94%	-41.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$910.0K	-$17.00K
YoY Change	5252.94%	-41.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$4.340M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$7.000K	$4.334M
YoY Change	-100.16%	-17436.0%
NET CHANGE
Cash From Operating Activities	-$1.948M	-$2.439M
Cash From Investing Activities	-$910.0K	-$17.00K
Cash From Financing Activities	-$7.000K	$4.334M
Net Change In Cash	-$2.865M	$1.878M
YoY Change	-252.56%	-172.31%
FREE CASH FLOW
Cash From Operating Activities	-$1.948M	-$2.439M
Capital Expenditures	$910.0K	$17.00K
Free Cash Flow	-$2.858M	-$2.456M
YoY Change	16.37%	-4.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017Q2	csbr	Assetsin Progress Gross AssetsinProgressGross	472000	USD
CY2017Q3	csbr	Assetsin Progress Gross AssetsinProgressGross	141000	USD
CY2016Q3	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	474000	USD
CY2017Q3	csbr	Cost Of Personalized Oncology Solutions CostOfPersonalizedOncologySolutions	387000	USD
CY2016Q3	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2049000	USD
CY2017Q3	csbr	Cost Of Translational Oncology Solutions CostOfTranslationalOncologySolutions	2255000	USD
CY2014Q4	csbr	Monthly Capital Lease Payment MonthlyCapitalLeasePayment	3000	USD
CY2017Q3	csbr	Numberof Operating Subsidiaries NumberofOperatingSubsidiaries	2	subsidiary
CY2017Q3	csbr	Percentof Revenue Growth PercentofRevenueGrowth	0.38
CY2016Q3	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	511000	USD
CY2017Q3	csbr	Personalized Oncology Solutions PersonalizedOncologySolutions	439000	USD
CY2017Q3	csbr	Property Plantand Equipment Cost Capitalization Amount PropertyPlantandEquipmentCostCapitalizationAmount	100000	USD
CY2017Q3	csbr	Reductionin Cash Usedin Operating Activities ReductioninCashUsedinOperatingActivities	3600000	USD
CY2017Q3	csbr	Reductionin Net Loss ReductioninNetLoss	3600000	USD
CY2017Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Aggregate Intrinsic Value Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsAggregateIntrinsicValueGranted		USD
CY2017Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Options Grant In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOptionsGrantInPeriodWeightedAverageRemainingContractualTerm	P6Y1M1D
CY2017Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Canceled In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCanceledInPeriod	0	shares
CY2017Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Options Granted Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
CY2017Q3	csbr	Share Based Compensation Arrangement By Share Based Payment Award Warrants Outstanding ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsOutstanding	2004284	shares
CY2017Q3	csbr	Share Based Compensation Arrangements By Share Based Payment Award Options Canceled In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCanceledInPeriodWeightedAverageExercisePrice	0.00
CY2016Q3	csbr	Translational Oncology Solutions TranslationalOncologySolutions	3159000	USD
CY2017Q3	csbr	Translational Oncology Solutions TranslationalOncologySolutions	4594000	USD
CY2017Q3	csbr	Working Capital Deficit WorkingCapitalDeficit	0	USD
CY2017Q3	dei	Amendment Flag AmendmentFlag	false
CY2017Q3	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--04-30
CY2017Q3	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2017Q3	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2017Q3	dei	Document Period End Date DocumentPeriodEndDate	2017-07-31
CY2017Q3	dei	Document Type DocumentType	10-Q
CY2017Q3	dei	Entity Central Index Key EntityCentralIndexKey	0000771856
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	10985966	shares
CY2017Q3	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
CY2017Q3	dei	Entity Registrant Name EntityRegistrantName	CHAMPIONS ONCOLOGY, INC.
CY2017Q3	dei	Trading Symbol TradingSymbol	CSBR
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1852000	USD
CY2017Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1732000	USD
CY2017Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2274000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	685000	USD
CY2017Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2667000	USD
CY2017Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	551000	USD
CY2017Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1122000	USD
CY2017Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1164000	USD
CY2017Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	70991000	USD
CY2017Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	71555000	USD
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1129000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	564000	USD
CY2016Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4264788	shares
CY2017Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4506090	shares
CY2017Q2	us-gaap	Assets Assets	8011000	USD
CY2017Q3	us-gaap	Assets Assets	6467000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	5869000	USD
CY2017Q3	us-gaap	Assets Current AssetsCurrent	3457000	USD
CY2017Q3	us-gaap	Capital Lease Obligations Noncurrent CapitalLeaseObligationsNoncurrent	33000	USD
CY2017Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2017Q3	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	124000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due CapitalLeasesFutureMinimumPaymentsDue	62000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due Current CapitalLeasesFutureMinimumPaymentsDueCurrent	25000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due In Three Years CapitalLeasesFutureMinimumPaymentsDueInThreeYears	16000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Due In Two Years CapitalLeasesFutureMinimumPaymentsDueInTwoYears	27000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Interest Included In Payments CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments	4000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Present Value Of Net Minimum Payments CapitalLeasesFutureMinimumPaymentsPresentValueOfNetMinimumPayments	58000	USD
CY2017Q3	us-gaap	Capital Leases Future Minimum Payments Remainder Of Fiscal Year CapitalLeasesFutureMinimumPaymentsRemainderOfFiscalYear	19000	USD
CY2017Q3	us-gaap	Capital Leases Of Lessee Contingent Rentals Basis Spread On Variable Rate CapitalLeasesOfLesseeContingentRentalsBasisSpreadOnVariableRate	0.05
CY2017Q2	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	872000	USD
CY2017Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	917000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2585000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4463000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3295000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	430000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	400000	USD
CY2016Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1878000	USD
CY2017Q3	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2865000	USD
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11251844	shares
CY2017Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11251844	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10982159	shares
CY2017Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10982159	shares
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2017Q3	us-gaap	Common Stock Value CommonStockValue	11000	USD
CY2017Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4910000	USD
CY2017Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3737000	USD
CY2016Q3	us-gaap	Depreciation Depreciation	39000	USD
CY2017Q3	us-gaap	Depreciation Depreciation	36000	USD
CY2016Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	45000	USD
CY2017Q3	us-gaap	Depreciation And Amortization DepreciationAndAmortization	42000	USD
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	300371	USD
CY2017Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y
CY2017Q2	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	74000	USD
CY2017Q3	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	76000	USD
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1534000	USD
CY2017Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1209000	USD
CY2017Q2	us-gaap	Goodwill Goodwill	669000	USD
CY2017Q3	us-gaap	Goodwill Goodwill	669000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2532000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-670000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	14000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-387000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-120000	USD
CY2016Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	314000	USD
CY2017Q3	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	407000	USD
CY2016Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-51000	USD
CY2017Q3	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-134000	USD
CY2016Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-442000	USD
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1173000	USD
CY2016Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	20000	USD
CY2017Q3	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	0	USD
CY2016Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-94000	USD
CY2017Q3	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	60000	USD
CY2016Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	15000	USD
CY2017Q3	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	USD
CY2016Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	99000	USD
CY2017Q3	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	102000	USD
CY2017Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2017Q3	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	2000	USD
CY2017Q2	us-gaap	Liabilities Liabilities	7611000	USD
CY2017Q3	us-gaap	Liabilities Liabilities	6177000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8011000	USD
CY2017Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	6467000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	7447000	USD
CY2017Q3	us-gaap	Liabilities Current LiabilitiesCurrent	6020000	USD
CY2017Q2	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	918000	USD
CY2017Q3	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	2112000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4334000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-7000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-910000	USD
CY2016Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2439000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1948000	USD
CY2017Q3	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1900000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2546449	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-2546000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-674157	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-674000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-51000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	6193000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	5652000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2523000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-619000	USD
CY2017Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	107000	USD
CY2017Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	107000	USD
CY2017Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	164000	USD
CY2017Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	157000	USD
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-9000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-51000	USD
CY2016Q3	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	742000	USD
CY2016Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	17000	USD
CY2017Q3	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	910000	USD
CY2017Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	300000	USD
CY2017Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	360000	USD
CY2016Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4340000	USD
CY2017Q3	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017Q3	us-gaap	Property Plant And Equipment Additions PropertyPlantAndEquipmentAdditions	910000000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2338000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3248000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1216000	USD
CY2017Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2084000	USD
CY2016Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-2000	USD
CY2017Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	14000	USD
CY2016Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	6000	USD
CY2017Q3	us-gaap	Repayments Of Long Term Capital Lease Obligations RepaymentsOfLongTermCapitalLeaseObligations	7000	USD
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1211000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1118000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2017Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	150000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-69350000	USD
CY2017Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70024000	USD
CY2016Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	3670000	USD
CY2017Q3	us-gaap	Sales Revenue Services Net SalesRevenueServicesNet	5033000	USD
CY2016Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	925000	USD
CY2017Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	683000	USD
CY2016Q3	us-gaap	Share Based Compensation ShareBasedCompensation	1129000	USD
CY2017Q3	us-gaap	Share Based Compensation ShareBasedCompensation	564000	USD
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8710
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	0.9560
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	0.732
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0198
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0125
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.00750
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	2320431	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.85
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	1875	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	194977	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.79
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.84
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1282000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	1720000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2308704	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2501806	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.86
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.83
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	1720000	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	2501806	shares
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	2.83
CY2017Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	56529	USD
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0.00
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.76
CY2017Q3	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.51
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	1608000	USD
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y
CY2017	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M6D
CY2017Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y1M1D
CY2017Q3	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	400000	USD
CY2017Q3	us-gaap	Stockholders Equity StockholdersEquity	290000	USD
CY2017Q2	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2017Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	269685	shares
CY2017Q2	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2017Q3	us-gaap	Treasury Stock Value TreasuryStockValue	1252000	USD
CY2017Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	121000	USD
CY2017Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	121000	USD
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	9835279	shares
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10982159	shares
CY2016Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9835279	shares
CY2017Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10982159	shares

Files In Submission

Name	View Source	Status
0001628280-17-009317-index-headers.html	Edgar Link	pending
0001628280-17-009317-index.html	Edgar Link	pending
0001628280-17-009317.txt	Edgar Link	pending
0001628280-17-009317-xbrl.zip	Edgar Link	pending
csbr-20170731.xml	Edgar Link	completed
csbr-20170731.xsd	Edgar Link	pending
csbr-20170731_cal.xml	Edgar Link	unprocessable
csbr-20170731_def.xml	Edgar Link	unprocessable
csbr-20170731_lab.xml	Edgar Link	unprocessable
csbr-20170731_pre.xml	Edgar Link	unprocessable
csbr10-q7312017.htm	Edgar Link	pending
csbrq1731201710-qex311.htm	Edgar Link	pending
csbrq1731201710-qex312.htm	Edgar Link	pending
csbrq1731201710-qex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr

2017 Q3 Form 10-Q Financial Statement

#000162828017009317 Filed on September 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR CHAMPIONS ONCOLOGY, INC. Stock $csbr

2017 Q3 Form 10-Q Financial Statement

#000162828017009317 Filed on September 14, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CSBR
CHAMPIONS ONCOLOGY, INC. Stock $csbr